Despite saber-rattling, Congressional hearings, public shaming, rules regarding pricing transparency and more, the cost of spending on prescription drugs in the United States has actually increased and will likely do so for the next several years.

The IQVIA report finds that in 2018, 27% of drugs launched were for cancer or its symptoms, and 20% were for infectious diseases.

Medicare’s hospital insurance fund will be depleted in 2026, as previously forecast, and Social Security program costs are likely to exceed total income in 2020 for the first time since 1982, according to a government report.

Life science incubators and accelerators play a highly significant role in the industry and may be the key for regional growth, a new report shows.

Despite a decline over the past year of class action lawsuits, life science companies remain a popular target for securities fraud litigation.

The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.

Noting that from 1998 to 2017 there were about 146 failed shots at developing drugs for Alzheimer’s disease, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report on the state of the industry.

A new report indicates that the so-called “Brexit” will have a negative impact on healthcare in the United Kingdom.

International aid financing and innovation has helped to save nearly 700 million lives in the past 25 years, but those gains could be lost if momentum and political will wane, global health experts said.

For many people with a tear in the rubbery cartilage that cushions the knee, physical therapy may work just as well as surgery in terms of quieting pain and returning the joint’s function, a new study suggests.